Suzetrigine

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
Advertisement - Members don't see this ad
It is the perfect drug for knee scope, dental, breast aug, acute on chronic pain.

If the class proves out and they have successor drugs, we will be out of the schedule 2 business in 10 years.

Trulilicity was fda approved in 2014 and look at where tirzepatide is and what retatrutide is likely to be.
 
there will be a lot of surgeons who use this drug. interventional spine docs will want to write for something for acute radiculopathy.

the market for this drug for postsurgical pain is huge.



(we will never not be asked about schedule 2 drugs)
 
Advertisement - Members don't see this ad